Skip to main content

Table 2 Patient characteristics

From: Is a single portal venous phase in contrast-enhanced CT sufficient to detect metastases or recurrence in clear cell renal cell carcinoma? – a single-center retrospective study

  Total
Age [mean ± standard deviation] 67 ± 10 years
Sex [n] 27 male and 16 female
No treatment [n] 22 (51.2%)
Treatment with Checkpoint inhibitor (Nivolumab, Pembrolizumab+ Axitinib) [n] 12 (27.9%)
Treatment with tyrosine kinase inhibitor (Sorafenib, Cabozantinib, Pazopanib, Sunitinib) [n] 9 (20.9%)
Metastatic lesions divided by organ systems (total) [n] 155
Pulmonary [n] 31 (20.0%)
Lymphatic [n] 30 (19.4%)
Osseous [n] 18 (11.6%)
Hepatic [n] 16 (10.3%)
Adrenal [n] 13 (8.4%)
Peritoneal [n] 12 (7.7%)
Local [n] 11 (7.1%)
Contralateral kidney [n] 9 (5.8%)
Soft tissue [n] 8 (5.2%)
Pancreatic [n] 7 (4.5%)